IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.744
NA - Nord America 1.239
EU - Europa 715
OC - Oceania 33
SA - Sud America 24
AF - Africa 13
Totale 8.768
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 5.328
US - Stati Uniti d'America 1.196
HK - Hong Kong 803
CN - Cina 493
GB - Regno Unito 227
DE - Germania 118
IT - Italia 80
CZ - Repubblica Ceca 72
NL - Olanda 52
IN - India 51
CA - Canada 36
FI - Finlandia 33
AU - Australia 32
RU - Federazione Russa 31
BE - Belgio 21
JP - Giappone 17
UA - Ucraina 17
BR - Brasile 13
TR - Turchia 13
ZA - Sudafrica 11
ES - Italia 10
ID - Indonesia 9
EE - Estonia 8
SE - Svezia 8
FR - Francia 7
MX - Messico 6
AR - Argentina 5
PL - Polonia 5
CL - Cile 4
HU - Ungheria 4
TW - Taiwan 4
MY - Malesia 3
PT - Portogallo 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
GE - Georgia 2
IE - Irlanda 2
IR - Iran 2
KZ - Kazakistan 2
LT - Lituania 2
PK - Pakistan 2
SI - Slovenia 2
AM - Armenia 1
AT - Austria 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
YE - Yemen 1
Totale 8.768
Salva come PNG Salva come JPEG
Città #
Hong Kong 795
Singapore 422
Ashburn 305
Boardman 268
Hefei 230
London 200
Shanghai 145
Redmond 56
Munich 55
San Francisco 55
Brno 54
Los Angeles 49
Council Bluffs 45
Amsterdam 41
Pune 34
Rome 33
Santa Clara 27
Toronto 26
Washington 22
Turku 19
Melbourne 17
Olomouc 17
Hasselt 16
Seattle 16
West Jordan 16
Helsinki 14
Brooklyn 13
New York 13
Canberra 10
Guangzhou 9
São Paulo 9
Beijing 7
Chicago 7
Tokyo 7
Dallas 6
Haikou 6
Mexico City 6
Chennai 5
Hanover 5
Johannesburg 5
Manchester 5
New Delhi 5
Sydney 5
Bengaluru 4
Boston 4
Catania 4
Moscow 4
Oklahoma City 4
Paris 4
Phoenix 4
Shenzhen 4
St Petersburg 4
Stockholm 4
Tenri 4
The Dalles 4
Almere Stad 3
Budapest 3
Central 3
Dunstable 3
Genoa 3
Hangzhou 3
Ivanovo 3
Mol 3
Nizhniy Novgorod 3
North Liberty 3
Petaling Jaya 3
Poplar 3
Sona 3
Taipei 3
Tallinn 3
Warsaw 3
Wuhan 3
Alba 2
Ankara 2
Atlanta 2
Aversa 2
Berlin 2
Buenos Aires 2
Buffalo 2
Charlotte 2
Cincinnati 2
Denver 2
Dublin 2
Fremont 2
Gatchina 2
Hoellviken 2
Iowa City 2
Ljubljana 2
Lodz 2
Milan 2
Minsk 2
Nakano 2
Nuremberg 2
Penicuik 2
Porto 2
Prato 2
San Mateo 2
Sarajevo 2
Shanwei 2
Tbilisi 2
Totale 3.255
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 189
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 184
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 178
An investigation into thee mechanism of citrateFE2+-dependent lipid peroxidation 176
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 175
Cancer drugs and QT prolongation: weighing risk against benefit 175
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 174
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 168
A supposed role for superoxide dismutase in the control of tumor growth 167
Minimal sampling colistin pharmacokinetics in critically ill patients 165
A Special Section on Clinical Pharmacology-Editorial 164
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 164
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 162
Cardio-oncology in clinical studies and real life 161
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 160
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 159
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 156
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 152
Adriamycin dependent release of iron from human lung tumor microsomes : Biochemical mechanisms and clinical implications 150
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 148
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 148
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 144
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 130
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 110
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 102
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 98
Anthracyclines 97
Anthracycline Cardiotoxicity 93
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 92
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 87
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 87
Anthracycline Cardiotoxicity 80
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 80
Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Mol Brain Res. 79
Anthracycline cardiotoxicity 79
An Invitation from the Editors of Cardio-Oncology 77
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 76
Adriamycin dependent release of iron from microsomal membranes 75
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 73
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting 72
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 71
An introduction to the metabolic determinants of anthracycline cardiotoxicity 69
Cardiotoxicity of antitumor drugs 65
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 63
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 61
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 54
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 37
What is cardiotoxicity? 37
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 37
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 33
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 31
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 31
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 30
Pharmacology of Cardio-Oncology 30
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 29
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 29
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 29
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 28
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 28
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 28
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 27
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 27
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. 26
Pixantrone: novel mode of action and clinical readouts. 26
Isavuconazole: case report and pharmacokinetic considerations 25
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 25
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 25
Cardiac imaging in childhood cancer survivors: a state-of-the-art review 24
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 24
Drug-induced hepatotoxicity in cancer patients - implication for treatment 24
Redox cycling of iron and lipid peroxidation 23
Cardiotoxicity of antitumor drugs 23
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 23
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 23
Quantitative evaluation of the activity of the malate-aspartate shuttle in Ehrlich ascites tumor cells. 22
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 22
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 22
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 22
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 22
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 22
Role of iron in anthracycline cardiotoxicity : New tunes for an old song ? 22
null 21
Cardiotoxic effects of anthracycline-taxane combinations 21
The role of iron in the initiation of lipid peroxidation. 21
Matters of the heart: The case of TNF-alpha targeting drugs 21
New frontiers in Cardio-Oncology 21
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 21
Development of a tumor-specific photoactivatable doxorubicin prodrug. 21
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 21
Novel mechanisms for the inhibition of low density lipoprotein oxidation by ascorbic acid. 21
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. 21
Fe(II) oxidation and Fe(III) incorporation by the M(r) 66,000 microsomal iron protein that stimulates NADPH oxidation 20
Doxorubicin metabolism and toxicity in human myocardium : Role of cytoplasmic deglycosidation and carbonyl reduction 20
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 20
Editorial: The Journal Chemotherapy Is for Cardio-Oncologists Too 20
Treatment specific toxicities: Hormones, antihormones, radiation therapy. 20
Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. 20
Factors influencing superoxide and t-BuOOH dependent lipid peroxidation of tumor microsomes 20
The concomitant management of cancer therapy and cardiac therapy 20
Lipid peroxidation of microsomes from Morris hepatoma 3924A : order parameter and dynamic properties determined by fluorescence anisotropy decay 20
Totale 6.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.804
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.804
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022527 0 5 0 1 0 1 2 214 7 7 7 283
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024776 22 87 29 55 96 329 9 29 6 24 10 80
2024/20257.426 150 67 268 29 72 168 91 32 690 586 2.541 2.732
2025/2026109 109 0 0 0 0 0 0 0 0 0 0 0
Totale 8.946